Choice of Contraceptives
May 15, 2023 (Issue: 1676)
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone,...more
- S Teal and A Edelman. Contraception selection, effectiveness, and adverse effects: a review. JAMA 2021; 326:2507. doi:10.1001/jama.2021.21392
- CDC. US medical eligibility criteria for contraceptive use, 2016 (US MEC). Available at: https://bit.ly/41CuyLG. Accessed April 27, 2023.
- MF Gallo et al. 20 μg versus >20 μg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013; 8:CD003989. doi:10.1002/14651858.cd003989.pub5
- G Grandi et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol 2020; 13:327. doi:10.1080/17512433.2020.1750365
- Estetrol/drospirenone (Nextstellis) – a new combination oral contraceptive. Med Lett Drugs Ther 2021; 63:101.
- MK Trivedi et al. A review of hormone-based therapies to treat adult acne vulgaris in women. Int J Womens Dermatol 2017; 3:44. doi:10.1016/j.ijwd.2017.02.018
- L Iversen et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study. BMJ 2018; 362:k3609. doi:10.1136/bmj.k3609
- AR Brant et al. Non-contraceptive benefits of hormonal contraception: established benefits and new findings. Curr Obstet Gynecol Rep 2017; 6:109. doi:10.1007/s13669-017-0205-3
- R Słopień et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopause Rev 2018; 17:1. doi:10.5114/pm.2018.74895
- C Shufelt and A LeVee. Hormonal contraception in women with hypertension. JAMA 2020; 324:1451. doi:10.1001/jama.2020.11935
- L Morimont et al. Hormonal therapies and venous thrombosis: estrogen matters! Res Pract Thromb Haemost 2023; 7:100021. doi:10.1016/j.rpth.2022.100021
- Y Vinogradova et al. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015; 350:h2135. doi:10.1136/bmj.h2135
- C Oedingen et al. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: the role of the progestogen type and estrogen dose. Thromb Res 2018; 165:68. doi:10.1016/j.thromres.2018.03.005
- LS Mørch et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017; 377:2228. doi:10.1056/nejmoa1700732
- D Fitzpatrick et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case-control study and meta-analysis. PLoS Med 2023; 20:e1004188. doi:10.1371/journal.pmed.1004188
- CW Skovlund et al. Association of hormonal contraception with depression. JAMA Psychiatry 2016; 73:1154. doi:10.1001/jamapsychiatry.2016.2387
- FDA Guidance Document. Labeling for combined hormonal contraceptives guidance for industry. January 2018. Available at: https://bit.ly/3oC9czD. Accessed April 27, 2023.
- KB Simmons et al. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218:88. doi:10.1016/j.ajog.2017.07.003
- Drospirenone (Slynd) – a new progestin-only oral contraceptive. Med Lett Drugs Ther 2020; 62:18.
- C Zuniga et al. Effectiveness and efficacy rates of progestin-only pills: a comprehensive literature review. Contraception 2023; 119:109925. doi:10.1016/j.contraception.2022.109925
- JN Hultstrand et al. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: a nationwide register-based study. Lancet Reg Health Eur 2022; 21:100470. doi:10.1016/j.lanepe.2022.100470
- Twirla – a new contraceptive patch. Med Lett Drugs Ther 2021; 63:17.
- ACOG. Committee opinion No. 602: depot medroxyprogesterone acetate and bone effects. Obstet Gynecol 2014; 123:1398. doi:10.1097/01.aog.0000450758.95422.c8
- ACOG Committee on Practice Bulletins-Gynecology, Long- Acting Reversible Contraception Work Group. Practice bulletin No. 186: long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2017; 130:e251. doi:10.1097/aog.0000000000002400
- In brief: Etonogestrel (Nexplanon) contraceptive implant. Med Lett Drugs Ther 2012; 54:12.
- M Ali et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod 2016; 31:2491. doi:10.1093/humrep/dew222
- Liletta - a third levonorgestrel-releasing IUD. Med Lett Drugs Ther 2015; 57:99.
- Kyleena – another hormonal IUD. Med Lett Drugs Ther 2017; 59:38.
- KM Curtis and JF Peipert. Long-acting reversible contraception. N Engl J Med 2017; 376:461. doi:10.1056/nejmcp1608736
- JP Wu et al. Long-acting reversible contraception - highly efficacious, safe, and underutilized. JAMA 2018; 320:397. doi:10.1001/jama.2018.8877
- VK Cortessis et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol 2017; 130:1226. doi:10.1097/aog.0000000000002307
- DK Turok et al. Efficacy, safety, and tolerability of a new lowdose copper and nitinol intrauterine device: phase 2 data to 36 months. Obstet Gynecol 2020; 135:840. doi:10.1097/aog.0000000000003756
- SB Teal et al. Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. Obstet Gynecol 2019; 133:63. doi:10.1097/aog.0000000000003034
- Phexxi – a nonhormonal contraceptive gel. Med Lett Drugs Ther 2020; 62:129.
- ACOG. Practice bulletin summary No. 152: emergency contraception. Obstet Gynecol 2015; 126:685. doi:10.1097/01.aog.0000471179.25809.d8
- ND Goldstuck and D Wildemeersch. Practical advice for emergency IUD contraception in young women. Obstet Gynecol Int 2015; 2015:986439. doi:10.1155/2015/986439
- DK Turok et al. Levonorgestrel vs. copper intrauterine devices for emergency contraception. N Engl J Med 2021; 384:335. doi:10.1056/nejmoa2022141
- G Piaggio et al. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 2011; 84:35. doi:10.1016/j.contraception.2010.11.010
- K Cleland et al. Emergency contraception review: evidencebased recommendations for clinicians. Clin Obstet Gynecol 2014; 57:741. doi:10.1097/grf.0000000000000056
- M Endler et al. Effect of levonorgestrel emergency contraception on implantation and fertility: a review. Contraception 2022; 109:8. doi:10.1016/j.contraception.2022.01.006
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Choice of Contraceptives
Article code: 1676a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
